Core Viewpoint - The certainty of the global weight loss drug market reaching $150 billion in the next decade has significantly decreased due to price reductions of GLP-1 drugs by Novo Nordisk and Eli Lilly, alongside increasing competition in the self-pay market [1][8]. Market Predictions - Analysts have revised down the market size forecast for 2030 by approximately 30% to around $100 billion, with some institutions pushing the $150 billion peak target to 2035 [1][8]. - Jefferies has lowered its peak market expectation from over $100 billion in the early 2030s to $80 billion, a 20% reduction from earlier predictions [1][8]. Company Performance - Novo Nordisk and Eli Lilly, the leading companies in the weight loss drug market, are set to release their Q4 financial reports soon, with Eli Lilly's market capitalization surpassing $1 trillion last year [2][9]. - Analysts expect Novo Nordisk to forecast a decline in sales and operating profit for 2026, while Eli Lilly is projected to see over 21% revenue growth compared to 2025 [2][9]. Price Dynamics - Goldman Sachs has adjusted its 2030 market size prediction from $130 billion to $105 billion due to accelerated price declines and changes in consumer medication patterns [4][11]. - The initial retail price for Novo Nordisk's and Eli Lilly's drugs was around $1,000 per month, but due to political pressure, the current price has dropped to between $149 and $299 per month [4][11]. Prescription Trends - Recent data shows that the total prescriptions for GLP-1 drugs reached 730,000 in the week ending January 23, with a 4% increase in new prescriptions for Novo Nordisk's products, driven mainly by the new oral formulation [11][12]. Market Outlook - Some institutions remain optimistic, with Pfizer's CEO predicting a $150 billion market size by 2030, and Montreal Bank projecting $158 billion in sales by 2033, attributing potential growth to price reductions [6][13]. - Analysts from various firms express that if self-pay market sales can offset price declines, there is still room for upward adjustments in market size predictions [14].

Core Insights - The current obstacles for individuals seeking treatment for obesity through GLP-1 drugs include production bottlenecks, high costs, and insurance reimbursement issues, particularly for seniors on Medicare [2][5] - Psychological barriers also exist, as some individuals are resistant to injectable treatments, preferring not to undergo weekly injections [5] Industry Outlook - By 2026, these barriers are expected to diminish, with drug prices decreasing, expanded insurance coverage, and the anticipated introduction of oral formulations [6] - This shift is projected to significantly increase the population using GLP-1 drugs, representing a major benefit for public health and creating new investment opportunities [6]